The invention relates to a compound of formula (I)
wherein R1 to R4 and n are defined as in the description and in the claims. The compound of formula (I) can be for treating.
本发明涉及一种式 (I) 的化合物
其中 R1 至 R4 和 n 的定义见说明书和权利要求书。式(I)化合物可用于治疗:
TRIAZOLO[4,5-D]PYRIMIDINES AS AGONISTS OF THE CANNABINOID RECEPTOR 2
申请人:F. Hoffmann-La Roche AG
公开号:EP3215506A1
公开(公告)日:2017-09-13
NOVEL TRIAZOLO[4,5-D]PYRIMIDINES
申请人:Hoffmann-La Roche Inc.
公开号:US20170204103A1
公开(公告)日:2017-07-20
The invention relates to a compound of formula (I)
wherein R
1
to R
4
and n are defined as in the description and in the claims. The compound of formula (I) can be for treating.
[EN] TRIAZOLO[4,5-D]PYRIMIDINES AS AGONISTS OF THE CANNABINOID RECEPTOR 2<br/>[FR] TRIAZOLO[4,5-D]PYRIMIDINES COMME AGONISTES DU RÉCEPTEUR CANNABINOÏDE 2
申请人:HOFFMANN LA ROCHE
公开号:WO2016071375A1
公开(公告)日:2016-05-12
The invention relates to a compound of formula (I) wherein R1to R4and n are defined as in the description and in the claims. The present invention relates to organic compounds useful for therapy and/or prophylaxis in a mammal, and in particular to compounds that are preferential agonists of the Cannabinoid Receptor 2.